NCT01207492 2026-02-20
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
71 trialsNCT07413263 2026-02-18
Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients
Assiut University
Not yet recruiting
NCT04903119 2026-02-13
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
University of Kentucky
Phase 1 Recruiting
NCT01407198 2025-12-19
Nilotinib With Radiation for High Risk Chordoma
Massachusetts General Hospital
Phase 1 Completed
NCT04626024 2025-12-19
TOKIN
Baylor College of Medicine
Phase 2 Recruiting
NCT01316250 2025-10-02
Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
American University of Beirut Medical Center
Phase NA Completed
NCT02201459 2025-10-02
PETALs
Hospices Civils de Lyon
Phase 3 Completed
NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
NCT04838041 2025-07-30
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Medical College of Wisconsin
Phase 2 Recruiting
NCT06409936 2025-07-08
PEARL
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Recruiting
NCT04205903 2025-06-29
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01860456 2025-06-05
TIKlet
University of Pisa
Completed
NCT01751425 2025-06-03
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01804985 2025-03-14
DESTINY
University of Liverpool
Phase 2 Completed
NCT03906292 2025-03-10
CMLXI
University of Jena
Phase 2 Active not recruiting
NCT04147533 2024-11-26
HALF
Masaryk University
Phase 2 Active not recruiting
NCT02326311 2024-08-13
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 3 Completed
NCT02001818 2024-08-06
PInNACLe
Australasian Leukaemia and Lymphoma Group
Phase 2 Completed
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT01657604 2023-05-10
TIGER
University of Jena
Phase 3 Completed
NCT02269267 2023-03-03
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
Medical College of Wisconsin
Phase 2 Completed
NCT03885830 2023-01-11
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
UNC Lineberger Comprehensive Cancer Center
Completed
NCT01774630 2022-08-18
NiloPost-STIM
University Hospital, Bordeaux
Phase 2 Completed
NCT04006847 2022-07-01
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT02353728 2022-03-25
Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy
Weill Medical College of Cornell University
Phase 2 Completed
NCT03942094 2022-03-16
Nilotinib for First-line Newly Diagnosed CML-CP Patients
Shenzhen Second People's Hospital
Phase 3 Unknown
NCT02602314 2022-01-20
SUSTRENIM
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 4 Unknown
NCT00481052 2022-01-18
CML0307
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT00769327 2022-01-04
CML0408
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT02973711 2021-02-16
A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
University of Michigan Rogel Cancer Center
Phase 1/2 Withdrawn
NCT01856283 2021-01-13
Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells
Niguarda Hospital
Phase 2 Completed
NCT01702064 2021-01-05
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01914484 2020-11-02
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
University Health Network, Toronto
Phase 1/2 Completed
NCT01528085 2020-07-30
Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Goethe University
Phase 2 Completed
NCT01140568 2020-05-05
Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
University of California, San Diego
Phase 2 Completed
NCT01155817 2020-04-15
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Stanford University
Phase 1 Completed
NCT02225574 2020-02-12
An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00036738 2020-01-29
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00976612 2020-01-07
Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK
Asan Medical Center
Completed
NCT02174445 2019-12-02
DECLINE
University Hospital Freiburg
Phase 3 Terminated
NCT00129740 2019-09-24
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02421926 2019-07-08
IDEAL-E
Asan Medical Center
Withdrawn
NCT01294618 2019-05-28
NILOPEG
Hospices Civils de Lyon
Phase 2 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT01871311 2019-02-08
A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors
Georgetown University
Phase 1 Terminated
NCT00788775 2018-11-15
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02709083 2018-11-02
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Emory University
Phase 2 Terminated
NCT01866553 2018-10-12
Nilotinib Plus Pegylated Interferon-α2b in CML
Amsterdam UMC, location VUmc
Phase 2 Terminated
NCT01535391 2018-08-06
CML0811
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3 Completed
NCT03331211 2017-11-08
Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia
Nanfang Hospital, Southern Medical University
Unknown